Cabometyx® (cabozantinib) – New indication
March 26, 2025 - Exelixis announced the FDA approval of Cabometyx (cabozantinib), for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
Top